Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMT13EW)

• Drug Name: AMINOBENZTROPINE Drug Info
• Synonyms: Aminobenztropine; CHEMBL330957; 88097-86-3; 3-(2'-Aminobenzhydryloxy)tropane; ABHT; Aminobenztropine, solid; Spectrum_000273; SpecPlus_000797; Spectrum5_001758; Spectrum4_001211; Spectrum3_000745; AC1L1D0L; AC1Q57ZN; Lopac0_000126; KBioGR_001642; BSPBio_002330; KBioSS_000753; MLS000859976; SPECTRUM2300334; DivK1c_006893; SCHEMBL1231000; 2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)oxy-phenylmethyl]aniline; KBio3_001550; KBio2_003321; KBio1_001837; KBio2_005889; KBio2_000753; CTK5F9344; CHEBI:125384; HMS3260I14; HMS3374M03; HMS2232P19

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2143
  ChEBI ID: CHEBI:125384
  CAS Number: CAS 88097-86-3
  TTD Drug ID: DMT13EW

Molecule-Related Drug Atlas

Drug(s) Targeting Muscarinic acetylcholine receptor M1 (CHRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACECLIDINE	DMOLNCZ	Glaucoma/ocular hypertension	9C61	Approved	[2]
Fesoterodine fumarate	DM13495	Overactive bladder	GC50.0	Approved	[3]
SMT-D002	DM1I93C	Seborrhea	ED91.2	Approved	[4]
Clidinium	DMUMQZ0	Abdominal stomach pain	DD91.4	Approved	[5]
Trihexyphenidyl	DMB19L8	Dystonia	8A02	Approved	[6]
Oxyphenonium	DMMQHOZ	Visceral spasms	MD81.4	Approved	[7]
Benztropine	DMGZOVN	Parkinson disease	8A00.0	Approved	[8]
Glycopyrrolate	DM2M3ZA	Anaesthesia	9A78.6	Approved	[9]
Pirenzepine	DMP6M1N	Peptic ulcer	DA61	Approved	[10]
Cycrimine	DM8C43Q	Parkinson disease	8A00.0	Approved	[11]

Drug(s) Targeting Dopamine transporter (DAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[12]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[13]
Methylphenidate	DM7SJD6	Attention deficit hyperactivity disorder	6A05.Z	Approved	[14]
Modafinil	DMYILBE	Malignant glioma	2A00.0	Approved	[15]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[16]
Ioflupane i-123	DMNARJT	Parkinson disease	8A00.0	Approved	[3]
DEXMETHYLPHENIDATE HYDROCHLORIDE	DM8WBAH	Attention deficit hyperactivity disorder	6A05.Z	Approved	[17]
Altropane	DMO9WDS	Attention deficit hyperactivity disorder	6A05.Z	Approved	[18]
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[19]
NAV5001	DMRSI1M	Dementia	6D80-6D86	Phase 3	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[1]
Muscarinic acetylcholine receptor M1 (CHRM1)	TTZ9SOR	ACM1_HUMAN	Inhibitor	[1]

References

• [1] 3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem. 1997 Mar 14;40(6):851-7.
• [2] Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
• [5] Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460.
• [6] The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301.
• [7] Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62.
• [8] Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60.
• [9] Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
• [10] Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31.
• [11] Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42.
• [12] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [13] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [14] Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [17] Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
• [18] Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).